Stockscreener 앱 받기
0.45
2.66%
-0.0123
시간 외 거래:
.46
0.01
+2.22%
전일 마감가:
$0.4623
열려 있는:
$0.473
하루 거래량:
85,431
Relative Volume:
0.27
시가총액:
$16.08M
수익:
-
순이익/손실:
$-12.29M
주가수익비율:
-0.4327
EPS:
-1.0399
순현금흐름:
$-9.07M
1주 성능:
-14.90%
1개월 성능:
-40.21%
6개월 성능:
-63.71%
1년 성능:
-63.71%
1일 변동 폭
$0.444
$0.4743
1주일 범위
$0.444
$0.5499
52주 변동 폭
$0.444
$1.73
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
명칭
Akari Therapeutics Plc Adr
전화
(929) 274-7510
주소
401 EAST JACKSON STREET, TAMPA
AKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.45 | 15.08M | 0 | -12.29M | -9.07M | -1.0399 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 개시 | Maxim Group | Buy |
| 2019-01-04 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | 업그레이드 | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | 재확인 | Chardan Capital Markets | Sell |
| 2016-07-11 | 개시 | Chardan Capital Markets | Sell |
모두보기
Akari Therapeutics Plc Adr 주식(AKTX)의 최신 뉴스
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer - Finviz
Akari Therapeutics appoints Kameel Farag as interim CFO By Investing.com - Investing.com South Africa
Why Akari Therapeutics Plc Depositary Receipt stock appeals to analystsWall Street Watch & Verified Momentum Stock Watchlist - newser.com
[PRE 14A] Akari Therapeutics Plc Preliminary Proxy Statement - Stock Titan
Akari Therapeutics Plc ADR (AKTX) looking to reclaim success with recent performance - Setenews
Akari Therapeutics forms scientific advisory board with Dr. Hurvitz By Investing.com - Investing.com South Africa
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP - The Manila Times
AKTX SEC FilingsAkari Therapeutics Plc 10-K, 10-Q, 8-K Forms - Stock Titan
What Wall Street predicts for Akari Therapeutics Plc Depositary Receipt stock priceMarket Performance Summary & Weekly Breakout Stock Alerts - newser.com
Akari Therapeutics appoints Kameel Farag as interim CFO - Investing.com India
Akari Therapeutics launches CEO Corner to enhance investor communications By Investing.com - Investing.com India
Form 424B5 Akari Therapeutics Plc - StreetInsider
Akari Therapeutics stock falls after $2.5 million registered offering - Investing.com
Akari Therapeutics secures $2.5 million through registered offering - Investing.com India
$2.5M raise: Akari Therapeutics to issue 3,125,000 ADSs in registered direct offering - Stock Titan
Akari Therapeutics files new patents for cancer treatment technology - Investing.com India
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 - Sahm
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
Will Akari Therapeutics Plc (Common Stock) (CLA) stock beat revenue estimatesWeekly Profit Analysis & Weekly Market Pulse Alerts - newser.com
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Sahm
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Akari’s ADC payload shows promise against resistant prostate cancer By Investing.com - Investing.com South Africa
Akari’s ADC payload shows promise against resistant prostate cancer - Investing.com India
First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan
Can momentum traders help lift Tripadvisor Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Analyzing PRA Group Inc. with risk reward ratio chartsJuly 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Institutional scanner results for ANSYS Inc.Entry Point & Verified Technical Trade Signals - newser.com
Does SRTY fit your quant trading modelPortfolio Gains Report & Stock Timing and Entry Methods - newser.com
Akari Therapeutics files patent for novel cancer treatment approach By Investing.com - Investing.com South Africa
Akari Therapeutics files patent for novel cancer treatment approach - Investing.com
Revolutionary Spliceosome Cancer Treatment: Akari Files Patent for First-in-Class ADC Platform Technology - Stock Titan
Is BSIIU stock reversal real or fake2025 Market Overview & Verified Swing Trading Watchlists - newser.com
Security Solutions Inc.2025 Market Outlook & Smart Money Movement Tracker - newser.com
Applying big data sentiment scoring on HLITJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Novel ADC Developer Akari Therapeutics to Showcase Pipeline at Major Healthcare Conference - Stock Titan
Next-Gen Cancer Drug Developer Akari Therapeutics Showcases Novel IO-Payload ADC Platform - Stock Titan
Advanced analytics toolkit walkthrough for Educational Development CorporationShare Buyback & Free Expert Approved Momentum Trade Ideas - Newser
What high frequency data says about MGTXOil Prices & Free Technical Confirmation Trade Alerts - Newser
Using AI based signals to follow BWXT2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser
Analyzing recovery setups for Guardian Pharmacy Services Inc. investorsMarket Volume Report & Weekly High Return Stock Forecasts - Newser
Akari Therapeutics completes $2.8 million note offering and extends warrant terms - Investing.com
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Cancer Drug Developer Akari Therapeutics Showcases Pipeline at Webull Biotech Conference - Stock Titan
Is BACQR still worth holding after the dipEquity Market Return Forecast Model Update - Newser
Insider Stock Buying Reaches US$1.79m On Akari Therapeutics - Sahm
Akari Therapeutics Reveals Breakthrough Progress in Cancer-Fighting Drug Development - Stock Titan
Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com India
Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan
Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan
INKT Stock Quote Price and Forecast - CNN
Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com
Akari Therapeutics Plc Adr (AKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Akari Therapeutics Plc Adr 주식 (AKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gaslightwala Abizer | CEO |
Aug 22 '25 |
Buy |
0.93 |
8,000 |
7,440 |
295,574 |
| Gaslightwala Abizer | CEO |
Aug 25 '25 |
Buy |
0.90 |
3,000 |
2,700 |
298,574 |
| Gaslightwala Abizer | President & CEO |
Jun 24 '25 |
Buy |
1.16 |
5,203 |
6,035 |
277,574 |
| Gaslightwala Abizer | President & CEO |
Jun 23 '25 |
Buy |
1.15 |
943 |
1,084 |
272,371 |
| Gaslightwala Abizer | President & CEO |
Jun 20 '25 |
Buy |
1.20 |
10,000 |
12,000 |
271,428 |
| Gaslightwala Abizer | President & CEO |
Jun 17 '25 |
Buy |
1.20 |
15,000 |
18,000 |
261,428 |
1.38%
1.42%
자본화:
|
볼륨(24시간):